SETD2-deficient HSPC can acquire the ability to overcome growth disadvantage during the latency period, eventually acquiring to the malignant hematopoietic features of myelodysplastic syndrome (MDS) (Zhang et al., 2018). This evidence concerns the gene SETD2 and myelodysplastic syndrome.